AngioDynamics Delivers Strong Q3 Results: Top-Line Growth and Profitability Expansion
Albany, NY – AngioDynamics, a leading medical technology company, reported strong fiscal third-quarter results, driven by impressive growth in its MedTech segment. The company's President and Chief Executive Officer, Jim Klemmer, was proud to announce that the quarter was "strong across the board," with top-line growth led by significant expansion in the MedTech business.
The MedTech segment, which includes the Auryon product portfolio, saw its nineteenth consecutive quarter of double-digit year-over-year revenue growth. This achievement underscores AngioDynamics' commitment to delivering high-quality products that meet the evolving needs of customers and patients.
Within this segment, Auryon continued to demonstrate exceptional momentum, driven by the company's ability to leverage its superior technology to take share in the market. The push into the hospital market has also yielded significant benefits, driving both top-line growth and better economics.
Moreover, AngioDynamics' strategic focus on expanding its adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) continued to pay off, with strong profitability reported across the board. The company's ability to navigate through a manufacturing transition, deal with tariffs, and manage macro uncertainty has been a testament to its resilience and commitment to delivering results.
The CEO expressed pride in the team's execution, stating that it was "years of work coming together" that had led to these outstanding results. He highlighted the company's strategy to drive profitable growth in high-margin, large MedTech markets as a key factor behind this success.
AngioDynamics also reported continued traction internationally following its CE mark approval for Auryon. The CEO expressed enthusiasm about the potential for future growth and expansion in new markets.
In addition to these highlights, the company's mechanical thrombectomy business saw positive developments during the quarter, with "loved what we saw" outcomes reported by management.
The conference call also featured an update on AngioDynamics' guidance for the full year. The CEO announced that the company was raising its net sales and adjusted EBITDA guidance for the third consecutive quarter, reflecting confidence in its growth trajectory and financial performance.
